NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 05 2021
27 05 2021
Historique:
received:
08
02
2021
accepted:
05
05
2021
entrez:
28
5
2021
pubmed:
29
5
2021
medline:
4
11
2021
Statut:
epublish
Résumé
Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. We consecutively enrolled a series of 397 newly diagnosed high-grade serous-advanced OC-patients. All patients were tested for BRCA-mutational-status and blood-parameters have been collected 48 h before staging-surgery. A significant correlation of NLR with disease distribution (p < 0.005) was found and patients with NLR < 4 underwent primary-debulking-surgery more frequently (p-value 0.001), with a lower surgical-complexity-score (p-value 0.002). Regarding survival-data, patients with NLR < 4 had a significant 7-month increase in mPFS (26 vs 19 months, p = 0.009); focusing on the BRCA-status, among both BRCA-mutated and BRCA-wild type patients, those with lower NLR had a significantly prolonged mPFS compared to patients with NLR > 4 (BRCA-mutated: 35 vs 23 months, p = 0.03; BRCA-wt: 19 vs 16 months, p = 0.05). At multivariate-analysis, independent factors of prolonged PFS were BRCA mutational status, having received complete cytoreduction and NLR < 4. Also, the strongest predictors of longer OS were BRCA-mutational status, having received complete cytoreductive surgery, NLR < 4 and age. NLR is confirmed to be a prognostic marker in OC-patients and it seems unrelated with BRCA-mutational status.
Identifiants
pubmed: 34045513
doi: 10.1038/s41598-021-90361-w
pii: 10.1038/s41598-021-90361-w
pmc: PMC8159985
doi:
Substances chimiques
BRCA1 Protein
0
BRCA2 Protein
0
NLR Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11125Références
Ther Adv Med Oncol. 2020 Jul 24;12:1758835920944116
pubmed: 32782491
J Immunol. 1987 Oct 1;139(7):2406-13
pubmed: 2821114
Oncotarget. 2017 Aug 10;8(40):68938-68949
pubmed: 28978169
Mol Cell Oncol. 2019 Mar 13;6(2):1585170
pubmed: 31131303
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
Int J Colorectal Dis. 2014 Sep;29(9):1091-9
pubmed: 25048875
Clin Pharmacol Ther. 2010 Apr;87(4):401-6
pubmed: 20200512
Oncology. 2012;82(5):261-8
pubmed: 22538399
Biochem Pharmacol. 2021 Feb;184:114359
pubmed: 33285109
Gynecol Oncol. 2017 Jun;145(3):584-594
pubmed: 28222899
Chem Immunol Allergy. 2003;83:182-203
pubmed: 12947985
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
J Thorac Oncol. 2019 Aug;14(8):1440-1446
pubmed: 30999110
Br J Cancer. 2007 Nov 5;97(9):1266-70
pubmed: 17923866
Gynecol Oncol. 2018 Oct;151(1):10-17
pubmed: 30078505
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
J Immunol. 1985 Jan;134(1):230-4
pubmed: 3871101
Cell Physiol Biochem. 2017;41(6):2411-2418
pubmed: 28467978
Int Rev Immunol. 2010 Oct;29(5):459-60
pubmed: 20839910
Clin Cancer Res. 1999 Jun;5(6):1263-73
pubmed: 10389908
Cancer Immunol Immunother. 2020 Mar;69(3):383-397
pubmed: 31897661
Future Oncol. 2010 Jan;6(1):149-63
pubmed: 20021215
Clin Cancer Res. 2001 Mar;7(3 Suppl):947s-957s
pubmed: 11300496
J Pain Symptom Manage. 1997 Jan;13(1):1-9
pubmed: 9029856
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6
pubmed: 19318937
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Ann Oncol. 2018 Apr 1;29(4):924-930
pubmed: 29324972
Gynecol Oncol. 2018 Jul;150(1):31-37
pubmed: 29751991
BMC Cancer. 2014 Feb 21;14:117
pubmed: 24559042
Trends Cancer. 2019 Sep;5(9):524-528
pubmed: 31474356
Oncotarget. 2016 May 31;7(22):33210-9
pubmed: 27120807
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Gynecol Oncol. 2015 Oct;139(1):5-9
pubmed: 26196319
Hematol Oncol Clin North Am. 2018 Dec;32(6):xiii-xiv
pubmed: 30390771
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Target Oncol. 2018 Aug;13(4):469-479
pubmed: 29948780
Gynecol Oncol. 2011 Jan;120(1):23-8
pubmed: 20933255
Lancet. 2009 Oct 17;374(9698):1371-82
pubmed: 19793610
Br J Cancer. 2011 Apr 12;104(8):1288-95
pubmed: 21448173
Gynecol Oncol. 2020 Sep;158(3):740-746
pubmed: 32553590
PLoS One. 2016 May 20;11(5):e0156101
pubmed: 27203425
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
J Ovarian Res. 2020 May 15;13(1):59
pubmed: 32414391
Int J Gynecol Cancer. 2020 Sep;30(9):1378-1383
pubmed: 32788264
Lung Cancer. 2017 Apr;106:1-7
pubmed: 28285682
BMC Cancer. 2013 Jul 22;13:350
pubmed: 23876227
J Surg Oncol. 2005 Sep 1;91(3):181-4
pubmed: 16118772
Sci Rep. 2015 Jul 31;5:11026
pubmed: 26226887
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Arch Immunol Ther Exp (Warsz). 2001;49(1):63-9
pubmed: 11266093
Arch Gynecol Obstet. 2018 Apr;297(4):849-857
pubmed: 29368160